Debra L. Fleenor
Bosch
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Debra L. Fleenor.
BMC Neuroscience | 2007
Iok-Hou Pang; H. Zeng; Debra L. Fleenor; Abbot F. Clark
BackgroundRetinal ganglion cells (RGCs) are responsible for the transmission of visual signals to the brain. Progressive death of RGCs occurs in glaucoma and several other retinal diseases, which can lead to visual impairment and blindness. Pigment epithelium-derived factor (PEDF) is a potent antiangiogenic, neurotrophic and neuroprotective protein that can protect neurons from a variety of pathologic insults. We tested the effects of PEDF on the survival of cultured adult rat RGCs in the presence of glaucoma-like insults, including cytotoxicity induced by glutamate or withdrawal of trophic factors.ResultsCultured adult rat RGCs exposed to glutamate for 3 days showed signs of cytotoxicity and death. The toxic effect of glutamate was concentration-dependent (EC50 = 31 μM). In the presence of 100 μM glutamate, RGC number decreased to 55 ± 4% of control (mean ± SEM, n = 76; P < 0.001). The glutamate effect was completely eliminated by MK801, an NMDA receptor antagonist. Trophic factor withdrawal also caused a similar loss of RGCs (54 ± 4%, n = 60, P < 0.001). PEDF protected against both insults with EC50 values of 13.6 ng/mL (glutamate) and 3.4 ng/mL (trophic factor withdrawal), respectively. At 100 ng/mL, PEDF completely protected the cells from both insults. Inhibitors of the nuclear factor κB (NFκB) and extracellular signal-regulated kinases 1/2 (ERK1/2) significantly reduced the protective effects of PEDF.ConclusionWe demonstrated that PEDF potently and efficaciously protected adult rat RGCs from glutamate- and trophic factor withdrawal-mediated cytotoxicity, via the activation of the NFκB and ERK1/2 pathways. The neuroprotective effect of PEDF represents a novel approach for potential treatment of retinopathies, such as glaucoma.
Investigative Ophthalmology & Visual Science | 2010
Jia Ma; Wenhan Yu; Yun Wang; Guiqun Cao; Suping Cai; Xiaoming Chen; Naihong Yan; Yuansheng Yuan; H. Zeng; Debra L. Fleenor; Xuyang Liu; Iok-Hou Pang
PURPOSE. To evaluate the potential neuroprotective effects of C-type natriuretic peptide (CNP) on rat retinal ganglion cells (RGCs). METHODS. Cultured adult rat retinal cells were treated with vehicle, CNP, or atrial natriuretic peptide (ANP), followed by cytotoxic insults (glutamate, TNFalpha, or withdrawal of trophic factor). RGC survival was analyzed by counting Thy-1-positive cells in each well. For in vivo evaluation, N-methyl-d-aspartate (NMDA) with or without CNP was injected intravitreally into rat eyes. At various time points after injection, retinal cross-sections were analyzed for thickness changes in the retinal layers, and retinal flat mounts were assessed by counting cresyl violet-labeled or TUNEL-positive cells. Expressions of natriuretic peptide receptor-B (NPRB) and apoptosis-related genes in retina, including Bcl-xL, BAX, and micro-calpain, were analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). RESULTS. At 50 and 500 nM, CNP, but not ANP, significantly (P < 0.05) protected against glutamate-insult and trophic factor withdrawal-induced RGC death in vitro. Neither peptide significantly affected TNFalpha-induced cytotoxicity. Intravitreal injection of NMDA (20 nanomoles) significantly (P < 0.05) decreased the thickness of the inner plexiform layer (IPL), induced cell loss, increased the number of TUNEL-positive cells in the RGC layer, and upregulated the expression of Bcl-xL, BAX, and micro-calpain. All these effects were significantly (P < 0.05) alleviated by concomitant injection of CNP (4.5 nmol, 10 microg). The neuroprotective effects of CNP were maintained up to 14 days after CNP injection. CONCLUSIONS. CNP protects rat RGCs against the apoptotic damage induced by insults such as excitatory amino acid, both in vitro and in vivo.
Investigative Ophthalmology & Visual Science | 2006
Debra L. Fleenor; Allan R. Shepard; Peggy E. Hellberg; Nasreen Jacobson; Iok-Hou Pang; Abbot F. Clark
Investigative Ophthalmology & Visual Science | 2007
Robert J. Wordinger; Debra L. Fleenor; Peggy E. Hellberg; Iok-Hou Pang; Tara O. Tovar; Gulab Zode; J. Fuller; Abbot F. Clark
Investigative Ophthalmology & Visual Science | 2003
Iok-Hou Pang; Peggy E. Hellberg; Debra L. Fleenor; Nasreen Jacobson; Abbot F. Clark
Investigative Ophthalmology & Visual Science | 2003
Debra L. Fleenor; Iok-Hou Pang; Abbot F. Clark
Investigative Ophthalmology & Visual Science | 2003
Iok-Hou Pang; Debra L. Fleenor; Peggy E. Hellberg; Karen Stropki; Mitchell D. McCartney; Abbot F. Clark
Archive | 2003
Debra L. Fleenor; Allan R. Shepard; Nasreen Jacobson; Iok-Hou Pang; Abbot F. Clark
Archive | 2006
Debra L. Fleenor; Iok-Hou Pang; Allan Shepard; Mark R. Hellberg; Abbot F. Clark; Peter G. Klimko
Archive | 2007
Debra L. Fleenor; Allan R. Shepard; Iok-Hou Pang